Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for carfilzomib or regorafenib; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; if approved, we or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib or regorafenib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, regorafenib or carfilzomib; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables)ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2011201020112010Revenue: Revenue from collaboration agreement

$  75,041$63,696$ 
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 Research and Markets  has announced ... Market Research Report 2014" report to their offering. ... Report 2014 presents comprehensive data on paracetamol (acetaminophen) markets ... Asia , North America ... (acetaminophen) description, covers its application areas and related patterns. ...
(Date:9/15/2014)... , Sept. 15, 2014 Sysmex America, ... information systems technology, announced today an amended distributorship ... is for Sysmex reagents, controls and instruments including ... ™ , Sysmex XP-300™, XT-Series and XN-Series ... is effective immediately and continues until August 31, ...
(Date:9/15/2014)... , Sept. 15, 2014  Mariel Therapeutics, Inc., ... Protein-7 and its application in Osteoarthritis (OA) and Chronic ... experts to its newly formed scientific advisory board. The ... and scientific resource to the company as it continues ... "We are honored to have such leading experts in ...
Breaking Medicine Technology:Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 2Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 3Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 4
... Mass., Aug. 25, 2011 Caliper Life Sciences, ... that its presentation at the Stifel Nicolaus Healthcare ... at 11:30 a.m. EDT.  Kevin Hrusovsky, President and ... on the company,s business. The live webcast can ...
... Aug. 25, 2011 PDI, Inc. (Nasdaq: ... promotional and commercialization services to health care companies, today ... Top 10 pharmaceutical company has been renewed for an ... PDI,s Shared Sales team beginning in September 2011 through ...
Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2
(Date:9/16/2014)... Dr. Eric Millstein of Beverly Hills is ... a specialty website devoted to the diagnosis and treatment ... lover and athlete, Dr. Millstein focuses on offering patients ... to maintain active, healthy lifestyles. , “We’re very excited ... specifically to ACL injuries and treatment,” says ...
(Date:9/16/2014)... 16, 2014 Lambda Solutions, a leader in ... is excited to welcome Stewart Rogers on board ... Executive at Lambda Solutions comments, “Product leadership will take Lambda ... to do so. Learning and talent management is at a ... help clinical learning and talent development in the past ten ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Online ... be offering $0 shipping on all kettlebell purchases in ... easy for customers to get started with this effective ... the Crossfit movement. The online store carries a variety ... and free weekly workouts guides. , “We’ve ...
(Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
(Date:9/16/2014)... 2014 Dakota Software , ... (EHS) and Sustainability management software, today announced that ... versatile software platform, MobileWorkflows, at their Annual Users ... MobileWorkflows allow for on-the-go access to Dakota’s enterprise-level ... Responsive Web Design, MobileWorkflows feature a streamlined user ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:Mobile EHS Compliance Tools the Focus of Dakota Software’s 2014 Users Conference 2
... In the report titled Millennium Ecosystem Assessment, scientists have said ... having a detrimental effect to human health and may cause ... malaria and cholera are threatening to cause a major outbreak ... beneficial factors of the eco system are being used in ...
... published in American Journal of Public Health, researchers had been ... causes of asthma in children by interventions due to health ... children in the age group of 4 to 12 yrs ... period of one year during which community health workers used ...
... US and Canadian scientists, consuming food with high glycemic index ... ,The study, which had spanned 16.6 years and observed ... that the risk is much significant for women who are ... often found in foods that have simple carbohydrates and sugars ...
... a data comprising of 5461 girls between 11 to 15 ... these girls more prone to stress fractures. ,The study ... physical activity, which often lasts for 16 or more hours ... of having a stress fracture than the girls doing physical ...
... market watchdog Food and Drug Administration had announced a series ... class of non-steroidal anti-inflammatory drugs that are sold with or ... of the drug Bextra (valdecoxib) from Pfizer, Inc. ... FDA had reports that the overall risk associated with the ...
... have completed the second phase of testing of the ... of cervical cancers and 90% of genital warts. ... for 36 months and regularly had gynecological examination, cervicovaginal ... serum antibodies to HPV. , ,The results showed ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: